Actively Recruiting
Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia
Led by Second Affiliated Hospital of Nanchang University · Updated on 2025-12-23
164
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).
CONDITIONS
Official Title
Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Myopia defined as spherical equivalent (SE) less than or equal to -0.5 diopters
- Age between 3 and 18 years, any gender
- Cylinder power less than or equal to 1.50 diopters
- Anisometropia (difference in SE between eyes) less than or equal to 1.50 diopters
- Willingness and ability to comply with study follow-up and signed informed consent form by subject or guardian
You will not qualify if you...
- Presence of other eye diseases
- Abnormal findings on slit-lamp eye examination
- Amblyopia, manifest strabismus, esotropia, or other congenital eye diseases
- Abnormal intraocular pressure or abnormal axial length of the eye
- One or both parents have spherical equivalent less than or equal to -6.00 diopters
- Other conditions deemed inconsistent with study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yifeng Yu
Nanchang, Jiangxi, China, 330008
Actively Recruiting
Research Team
Y
Yifeng Yu, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here